Venus Remedies secures final Rs. 11 crore payment from Cipla for AMR drug
The patented product, developed by Venus Medicine Research Centre (VMRC) for the treatment of multidrug-resistant (MDR) infections, was sold to Cipla in 2019
The patented product, developed by Venus Medicine Research Centre (VMRC) for the treatment of multidrug-resistant (MDR) infections, was sold to Cipla in 2019
Dr Reddy’s will pay Immutep US$ 20 million upfront and could deliver as much as US$ 349.5 million in regulatory and commercial milestones
Alport Syndrome is caused by genetic mutations affecting type IV collagen in the kidneys, ears, and eyes
Excelsior aims to make reshoring affordable and strategic, shielding nations from geopolitical disruptions
Peapod Bio’s proprietary technologies can efficiently identify inhibitors and binding molecules for virtually any target
Here's a new ray of hope for new hope for patients suffering from Meniere’s disease (MD) and sensorineural hearing loss
The FDA has classified recent submissions as a major amendment pushing the approval to its NDA for TransCon CNP back three months to February 28, 2026
This relates to the manufacture and supply of Human Recombinant Insulin (rh- Insulin) and Biosimilar Pegfilgrastim Drug Substance to the United States
The receipt of this order further strengthens the company's position in the global pharmaceutical market
Subscribe To Our Newsletter & Stay Updated